Literature DB >> 2455898

Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

P W Berman1, J E Groopman, T Gregory, P R Clapham, R A Weiss, R Ferriani, L Riddle, C Shimasaki, C Lucas, L A Lasky.   

Abstract

The major envelope glycoprotein, gp120, of human immunodeficiency virus type 1 (HIV-1) was purified from a Chinese hamster ovary cell line transfected with a truncated form of the HIV-1 env gene. The recombinant glycoprotein (rgp120) was formulated with aluminum hydroxide adjuvant and was used to immunize chimpanzees. The recombinant preparation was effective in eliciting cellular and humoral immunity as well as immunologic memory. Anti-rgp 120 antibodies reacted with authentic viral gp120 in immunological blot assays and were able to neutralize HIV-1 infectivity in vitro. Sera from the rgp120-immunized animals were able to neutralize HIV-1 pseudotypes of vesicular stomatitis virus prepared from the IIIB isolate, from which the gene encoding rgp120 was derived, as well as two heterologous isolates, ARV-2 and RF. The immune response elicited against the rgp120 was not effective in preventing viral infection after intravenous challenge with HIV-1. The implications of these results on HIV-1 vaccine development are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455898      PMCID: PMC281716          DOI: 10.1073/pnas.85.14.5200

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  A quantitative immunochemical measure of the primary interaction between I BSA and antibody.

Authors:  R S FARR
Journal:  J Infect Dis       Date:  1958 Nov-Dec       Impact factor: 5.226

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

4.  Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.

Authors:  L A Lasky; J E Groopman; C W Fennie; P M Benz; D J Capon; D J Dowbenko; G R Nakamura; W M Nunes; M E Renz; P W Berman
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

5.  Infection of chimpanzees with lymphadenopathy-associated virus.

Authors:  D P Francis; P M Feorino; J R Broderson; H M McClure; J P Getchell; C R McGrath; B Swenson; J S McDougal; E L Palmer; A K Harrison
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

6.  Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients.

Authors:  W G Robey; B Safai; S Oroszlan; L O Arthur; M A Gonda; R C Gallo; P J Fischinger
Journal:  Science       Date:  1985-05-03       Impact factor: 47.728

7.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

8.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

9.  Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS).

Authors:  R C Gallo; P S Sarin; E P Gelmann; M Robert-Guroff; E Richardson; V S Kalyanaraman; D Mann; G D Sidhu; R E Stahl; S Zolla-Pazner; J Leibowitch; M Popovic
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

Authors:  F D Veronese; A L DeVico; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

View more
  38 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Generation of deletion mutants of simian immunodeficiency virus incapable of proviral integration.

Authors:  K Prakash; P N Ranganathan; R Mettus; P Reddy; A Srinivasan; S Plotkin
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Neutralizing antibodies and antigens in AIDS.

Authors:  S G Norley; R Kurth
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  New FDA drug approval policies and HIV vaccine development.

Authors:  W K Mariner
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

5.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Authors:  N L Haigwood; P L Nara; E Brooks; G A Van Nest; G Ott; K W Higgins; N Dunlop; C J Scandella; J W Eichberg; K S Steimer
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Authors:  L O Arthur; J W Bess; D J Waters; S W Pyle; J C Kelliher; P L Nara; K Krohn; W G Robey; A J Langlois; R C Gallo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.

Authors:  A Pinter; W J Honnen; S A Tilley
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70.

Authors:  M H Gatei; H M Naif; S Kumar; D B Boyle; R C Daniel; M F Good; M F Lavin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.

Authors:  M J Irwin; L S Laube; V Lee; M Austin; S Chada; C G Anderson; K Townsend; D J Jolly; J F Warner
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.